

ATB-346

Catalog No: tcsc3091



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1226895-20-0

Formula:

$C_{21}H_{19}NO_3S$

Pathway:

Immunology/Inflammation

Target:

COX

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 51.6 mg/mL (141.20 mM)

Observed Molecular Weight:

365.45


Product Description

ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity.

IC50 value:

Target: COX-2

ATB-346 suppressed gastric prostaglandin E(2) synthesis as effectively as naproxen, but produced negligible damage in the stomach and intestine. Unlike naproxen and celecoxib, ATB-346 accelerated healing of pre-existing gastric ulcers. In a mouse airpouch model, ATB-346 suppressed cyclooxygenase-2 activity and inhibited leukocyte infiltration more effectively than naproxen. ATB-346 was as effective as naproxen in adjuvant-induced arthritis in rats, with a more rapid onset of activity. Unlike naproxen, ATB-346 did not elevate blood pressure in hypertensive rats [1]. Treatment with ATB-346 exhibited a significantly more rapid and sustained recovery of motor function, achieving greater than double the increase in locomotion score of the naproxen group by the 10th day of treatment. ATB-346 also significantly reduced the severity of inflammation (proinflammatory cytokines, apoptosis of neural tissue, and nitrosative stress) that characterized the secondary effects of SCI [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!